PFIZER INC Proceeds from (Repayments of) Debt, Maturing in More than Three Months
PFIZER INC (PFE) reported Proceeds from (Repayments of) Debt, Maturing in More than Three Months of $9.61 billion for the 9-month period ending 2011-10-02, per its 10-Q filed 2011-11-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfDebtMaturingInMoreThanThreeMonths · last filed 2011-11-10
- PFIZER INC proceeds from (repayments of) debt, maturing in more than three months for the quarter ending 2011-10-02 was $4.75B, a 212.79% increase year-over-year.
- PFIZER INC proceeds from (repayments of) debt, maturing in more than three months for the quarter ending 2011-07-03 was $2.19B.
- PFIZER INC proceeds from (repayments of) debt, maturing in more than three months for the quarter ending 2011-04-03 was $2.68B, a 41.75% increase year-over-year.
- PFIZER INC proceeds from (repayments of) debt, maturing in more than three months for the quarter ending 2010-10-03 was $1.52B.
| Period end | Proceeds from (Repayments of) Debt, Maturing in More than Three Months 3 month | Proceeds from (Repayments of) Debt, Maturing in More than Three Months 6 month | Proceeds from (Repayments of) Debt, Maturing in More than Three Months 9 month |
|---|---|---|---|
| 2011-10-02 | $4.75B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $6.93B derived: sum of 2 quarters · filed 2011-11-10 | $9.61B 10-Q · filed 2011-11-10 |
| 2011-07-03 | $2.19B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-11 | $4.87B 10-Q · filed 2011-08-11 | |
| 2011-04-03 | $2.68B 10-Q · filed 2011-05-12 | ||
| 2010-10-03 | $1.52B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $4.69B 10-Q · filed 2011-11-10 | |
| 2010-07-04 | $3.17B 10-Q · filed 2011-08-11 | ||
| 2010-04-04 | $1.89B 10-Q · filed 2011-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |